News
Samsung Biologics and Checkpoint Therapeutics Expand Manufacturing Partnership for Cosibelimab
Samsung Biologics Co., Ltd. and Checkpoint Therapeutics, Inc. announced the expansion of a long-term manufacturing partnership for Checkpoint’s anti-PD-L1 antibody, cosibelimab. Building upon an...
News
Wistar Scientists Creates a New Synthetic DNA Vaccine Against Powassan Virus
Scientists at The Wistar Institute have designed and tested the first-of-its-kind synthetic DNA vaccine against Powassan virus (POWV), targeting portions of the virus envelope...
News
Sanofi offers to acquire Kiadis, a clinical-stage company developing cell-based immunotherapy products
Sanofi and Kiadis, a clinical-stage biopharmaceutical company developing innovative ‘off the shelf’ natural killer (NK) cell based medicines for the treatment of life-threatening diseases,...
Press Releases
Lonza Announces Agreement to Manufacture AstraZeneca’s COVID-19 Long-Acting Antibody Combination
Lonza announced that the company has signed an agreement with AstraZeneca to manufacture AZD7442, a combination of two long-acting antibodies (LAABs) for the potential...
News
Global air cargo brand Turkish Cargo chosen as the best air cargo brand of Europe
Global air cargo brand Turkish Cargo chosen as the best air cargo brand of Europe The successful brand of national flag carrier Turkish Airlines,...
Clinical Trials
Novavax Provides Phase 3 COVID-19 Vaccine Clinical Development Update
Novavax, Inc., a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced updates on its Phase 3 clinical development program of NVX-CoV2373,...
Clinical Trials
Boehringer Ingelheim Begins Phase 2 Clinical Trial of a Targeted Therapy to Help People with Severe Respiratory Illness from COVID-19
Boehringer Ingelheim announced the initiation of a Phase 2 clinical trial of BI 764198, an inhibitor of TRPC6, a receptor-operated cation channel. This potent...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read